EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Health-related quality of life of children with X-linked hypophosphatemia in Germany

Martin Klein, Michael Obermaier, Helena Mutze, Sophia Maria Wilden, Mirko Rehberg iD, Karl Peter Schlingmann, Dorothee Schmidt, Oliver Metzing, Angela Hübner iD, Anette Richter-Unruh, Markus J Kemper, Marcus Weitz iD und 9 weitere

Pediatric Nephrology · 2024

DOI: 10.1007/s00467-024-06427-0 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Pediatric Nephrology, 2024. Verfasst von Martin Klein und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Social Sciences, Catholic University of Applied Sciences North Rhine, Westphalia, Cologne, Germany. Hauptthemen laut MEDLINE: Quality of Life, Familial Hypophosphatemic Rickets, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

X-linked hypophosphatemia (XLH) is a rare inherited phosphate-wasting disorder associated with bone and dental complications. Health-related quality of life (HRQoL) is reduced in XLH patients on conventional treatment with phosphate supplements and active vitamin D, while information on patients treated with burosumab is rare.

Methods

HRQoL was assessed in 63 pediatric XLH patients participating in a prospective, observational study and patient registry in Germany using the KIDSCREEN-52 survey instrument and standardized qualitative interviews.

Results

The median age of the XLH patients was 13.2 years (interquartile range 10.6 – 14.6). At the time of the survey, 55 (87%) patients received burosumab and 8 (13%) conventional treatment. Forty-six patients (84%) currently being treated with burosumab previously received conventional treatment. Overall, HRQoL was average compared to German reference values (mean ± SD: self-report, 53.36 ± 6.47; caregivers’ proxy, 51.33 ± 7.15) and even slightly above average in some dimensions, including physical, mental, and social well-being. In general, XLH patients rated their own HRQoL higher than their caregivers. In qualitative interviews, patients and caregivers reported that, compared with conventional therapy, treatment with burosumab reduced stress, bone pain, and fatigue, improved physical health, and increased social acceptance by peers and the school environment.

Conclusions

In this real-world study in pediatric XLH patients, HRQoL was average or even slightly above that of the general population, likely due to the fact that the vast majority of patients had their treatment modality switched from conventional treatment to burosumab resulting in improved physical health and well-being. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeFamilial Hypophosphatemic RicketsAntibodies, Monoclonal, HumanizedHumansChildGermanyMaleAdolescentFemaleProspective StudiesRegistriesSurveys and Questionnaires

Stichwörter der Autor:innen

AdolescentsChildrenHealth-related quality of lifeQuestionnaire KIDSCREEN-52Rare diseasesX-linked hypophosphatemia

Substanzen

burosumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Social Sciences, Catholic University of Applied Sciences North Rhine, Westphalia, Cologne, Germany.
  • Department of Pediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Cologne, Germany.
  • Department of General Pediatrics, Pediatric Nephrology, University Children's Hospital, Münster, Germany.
  • Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics and Adolescent Medicine, University of Lübeck, Lübeck, Germany.
  • University Children's Hospital, Jena, Germany.
  • Division of Pediatric Endocrinology, Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

ORCID-Profile: Mirko Rehberg, Angela Hübner, Marcus Weitz, Elke Wühl, Dirk Schnabel

Förderung

  • Medizinische Hochschule Hannover (MHH)

Zitieren

APA

Klein, M., Obermaier, M., Mutze, H., Wilden, S. M., Rehberg, M., Schlingmann, K. P., Schmidt, D., Metzing, O., Hübner, A., Richter-Unruh, A., Kemper, M. J., Weitz, M., Wühl, E., Jorch, N., Patzer, L., Freiberg, C., Heger, S., Ziviknjak, M., Schnabel, D., …, & German Society for Pediatric Nephrology (GPN) and the German Society for Pediatric and Adolescent Endocrinology and Diabetology (DGPAED) (2024). Health-related quality of life of children with X-linked hypophosphatemia in Germany. Pediatric Nephrology. https://doi.org/10.1007/s00467-024-06427-0

Vancouver

Klein M, Obermaier M, Mutze H, Wilden SM, Rehberg M, Schlingmann KP, et al. Health-related quality of life of children with X-linked hypophosphatemia in Germany. Pediatric Nephrology. 2024. doi:10.1007/s00467-024-06427-0

BibTeX
@article{Klein2024,
  author = {Klein, Martin and Obermaier, Michael and Mutze, Helena and Wilden, Sophia Maria and Rehberg, Mirko and Schlingmann, Karl Peter and Schmidt, Dorothee and Metzing, Oliver and Hübner, Angela and Richter-Unruh, Anette and Kemper, Markus J and Weitz, Marcus and Wühl, Elke and Jorch, Norbert and Patzer, Ludwig and Freiberg, Clemens and Heger, Sabine and Ziviknjak, Miroslav and Schnabel, Dirk and Haffner, Dieter and German Society for Pediatric Nephrology (GPN) and the German Society for Pediatric and Adolescent Endocrinology and Diabetology (DGPAED), German Society for Pediatric Nephrology (GPN) and the German Society for Pediatric and Adolescent Endocrinology and Diabetology (DGPAED)},
  title = {Health-related quality of life of children with X-linked hypophosphatemia in Germany},
  journal = {Pediatric Nephrology},
  year = {2024},
  doi = {10.1007/s00467-024-06427-0}
}
Kostenlos starten →